Aliases & Classifications for Diabetic Foot Ulcers

MalaCards integrated aliases for Diabetic Foot Ulcers:

Name: Diabetic Foot Ulcers 38 55
Diabetic Foot Ulcer 73
Diabetic Foot 73

External Ids:

Summaries for Diabetic Foot Ulcers

MalaCards based summary : Diabetic Foot Ulcers, also known as diabetic foot ulcer, is related to peripheral artery disease and arteries, anomalies of, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Diabetic Foot Ulcers is PDGFB (Platelet Derived Growth Factor Subunit B), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Saxagliptin and Clindamycin have been mentioned in the context of this disorder. Affiliated tissues include Bone, skin and bone, and related phenotypes are renal/urinary system and respiratory system

Wikipedia : 76 Diabetic foot ulcer is a major complication of diabetes mellitus, and probably the major component of... more...

Related Diseases for Diabetic Foot Ulcers

Diseases related to Diabetic Foot Ulcers via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 30.3 CCL2 IL6
2 arteries, anomalies of 30.1 CCL2 IL6 MMP9
3 vascular disease 29.9 CCL2 IL6 MMP9
4 scleritis 29.9 CCL2 MMP9
5 ischemic heart disease 29.8 CCL2 IL6
6 bone inflammation disease 29.7 CCL2 IL6
7 kidney disease 29.7 CCL2 IL6 TGFB1
8 chronic kidney failure 29.7 CALCA IL6 TGFB1
9 osteomyelitis 10.5
10 ischemia 10.3
11 depression 10.3
12 chronic ulcer of skin 10.2
13 melanoma 10.2
14 neuropathy 10.2
15 diabetes mellitus 10.2
16 limb ischemia 10.2
17 squamous cell carcinoma 10.2
18 peripheral vascular disease 10.1
19 critical limb ischemia 10.1
20 acute transverse myelitis 10.1 IL6 MMP9
21 transverse myelitis 10.1 IL6 MMP9
22 photokeratitis 10.1 IL6 MMP9
23 epithelial basement membrane dystrophy 10.1 MMP9 TGFB1
24 rosacea 10.1 IL6 MMP9
25 arteriovenous malformation 10.1 IL6 MMP9
26 laryngitis 10.1 IL6 TGFB1
27 posterior urethral valves 10.1 IL6 TGFB1
28 vitreous disease 10.1 CCL2 PDGFB
29 preterm premature rupture of the membranes 10.1 IL6 MMP9
30 appendicitis 10.1 IL6 MMP9
31 transient arthritis 10.1 IL6 TGFB1
32 tropical spastic paraparesis 10.1 IL6 MMP9
33 gingival disease 10.1 IL6 TGFB1
34 localized scleroderma 10.1 IL6 TGFB1
35 arthropathy 10.1
36 peripheral nervous system disease 10.1
37 rapidly involuting congenital hemangioma 10.1
38 idiopathic neutropenia 10.1 IL6 TGFB1
39 prostatitis 10.1 IL6 TGFB1
40 intervertebral disc disease 10.1 IL6 MMP9
41 rheumatic heart disease 10.1 IL6 TGFB1
42 lyme disease 10.1 IL6 MMP9
43 pelvic inflammatory disease 10.1 CCL2 MMP9
44 bacterial meningitis 10.1 IL6 MMP9
45 gingivitis 10.1 IL6 MMP9
46 denture stomatitis 10.1 CCL2 IL6
47 stachybotrys chartarum 10.1 CCL2 IL6
48 macular retinal edema 10.1 CCL2 IL6
49 ascending cholangitis 10.1 CCL2 TGFB1
50 post-thrombotic syndrome 10.1 CCL2 IL6

Graphical network of the top 20 diseases related to Diabetic Foot Ulcers:



Diseases related to Diabetic Foot Ulcers

Symptoms & Phenotypes for Diabetic Foot Ulcers

UMLS symptoms related to Diabetic Foot Ulcers:


seizures, tremor, angina pectoris, edema, back pain, pain, chest pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, muscle cramp

MGI Mouse Phenotypes related to Diabetic Foot Ulcers:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.26 IL6 MMP9 PDGFB TGFB1
2 respiratory system MP:0005388 8.92 IL6 MMP9 PDGFB TGFB1

Drugs & Therapeutics for Diabetic Foot Ulcers

Drugs for Diabetic Foot Ulcers (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Saxagliptin Approved Phase 4 361442-04-8 11243969
2
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
3
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
4
Aztreonam Approved Phase 4 78110-38-0 5362041 5742832
5
Tazobactam Approved Phase 4 89786-04-9 123630
6
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
7
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
8
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
9
Piperacillin Approved Phase 4 66258-76-2 43672
10
Metronidazole Approved Phase 4 443-48-1 4173
11
Alginic acid Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 9005-32-7
12
Petrolatum Approved, Investigational Phase 4,Phase 2 8009-03-8
13
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 55-56-1 2713 9552079
14
Dimenhydrinate Approved Phase 4 523-87-5 441281
15
Thrombin Approved, Investigational Phase 4,Not Applicable
16 Hypoglycemic Agents Phase 4,Phase 3,Phase 2
17 HIV Protease Inhibitors Phase 4,Phase 3,Not Applicable,Early Phase 1
18 Hormones Phase 4,Phase 3
19
protease inhibitors Phase 4,Phase 3,Not Applicable,Early Phase 1
20 Incretins Phase 4,Phase 3
21 Hormone Antagonists Phase 4,Phase 3
22 Dipeptidyl-Peptidase IV Inhibitors Phase 4,Phase 3
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
24 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
25 Antitubercular Agents Phase 4,Phase 3,Phase 2
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
28 Gentamicins Phase 4,Phase 3,Phase 2,Phase 1
29 Clavulanic Acids Phase 4,Not Applicable
30 Clindamycin palmitate Phase 4
31 Clindamycin phosphate Phase 4
32 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Coagulants Phase 4,Phase 3,Phase 1,Not Applicable
34 Hemostatics Phase 4,Phase 3,Phase 1,Not Applicable
35 Anti-Infective Agents, Local Phase 4,Phase 1,Phase 2,Not Applicable
36 Anesthetics Phase 4,Phase 1,Phase 2,Not Applicable
37 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Dermatologic Agents Phase 4,Phase 2
39
Nickel Phase 4 7440-02-0 934
40 Emollients Phase 4
41 Radiation-Protective Agents Phase 4
42 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
43 Disinfectants Phase 4,Phase 2
44 Chlorhexidine gluconate Phase 4,Phase 2,Not Applicable
45 Calcium, Dietary Phase 4,Phase 3,Phase 2,Not Applicable
46 Sitagliptin Phosphate Phase 4,Phase 3
47
Chitosan Approved Phase 3,Phase 1,Not Applicable 9012-76-4 71853
48
Becaplermin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 165101-51-9
49
Glucosamine Approved, Investigational Phase 3 3416-24-8 439213
50
AT-101 Approved, Investigational Phase 3 90141-22-3, 652-67-5 12597

Interventional clinical trials:

(show top 50) (show all 420)
# Name Status NCT ID Phase Drugs
1 A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers Unknown status NCT02081352 Phase 4
2 Maggot Debridement Therapy Versus Conventional Dressing Therapy to Treat Diabetic Foot Ulcers Unknown status NCT02816749 Phase 4
3 Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers Unknown status NCT02742233 Phase 4 saxagliptin;placebo
4 Outcomes of Non-infected Diabetic Foot Ulcers With/Without Antibiotics Unknown status NCT01418456 Phase 4 antibiotics
5 Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Unknown status NCT01951768 Phase 4 Garamycin Sponge (Gentamicin-Collagen sponge);Systemic Antibiotic
6 Clinical Evaluation of the SNaP Wound Care System Unknown status NCT01113658 Phase 4
7 Santyl Applications to Diabetic Foot Ulcers Completed NCT02111291 Phase 4
8 Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers Completed NCT01596920 Phase 4
9 LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers Completed NCT01454401 Phase 4
10 Study of Oasis Ultra in Diabetic Foot Ulcers Completed NCT01835379 Phase 4
11 LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers Completed NCT02224742 Phase 4
12 Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers Completed NCT00770939 Phase 4
13 A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers Completed NCT01143714 Phase 4 Santyl
14 Use of Santyl in Diabetic Foot Ulcers Completed NCT02581488 Phase 4
15 Diabetic Foot Ulcer Study on Topical Interventions Completed NCT02577900 Phase 4
16 Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers Completed NCT01143727 Phase 4 Santyl;Tegaderm Hydrogel
17 Using Santyl on Diabetic Foot Ulcers Completed NCT01408277 Phase 4
18 Diabetic Foot Ulcer. Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water Completed NCT02097615 Phase 4
19 Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers Completed NCT00235196 Phase 4
20 GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers Completed NCT02675855 Phase 4
21 OASIS Wound Matrix (Oasis) Mechanism of Action Completed NCT00570141 Phase 4
22 Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers Completed NCT00638872 Phase 4 Polydeoxyribonucleotide
23 Santyl vs. Sharp Debridement of Diabetic Foot Wounds Completed NCT01056198 Phase 4 Santyl
24 Hyperbaric Oxygen Therapy as Adjunctive Treatment of Chronic Diabetic Foot Ulcers Completed NCT00953186 Phase 4
25 Wound Edge Changes Following Treatment With Santyl Completed NCT01197898 Phase 4
26 Skin Ulcers Treatment With an Handicraft Topical Device Completed NCT02512159 Phase 4
27 GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds Completed NCT02260609 Phase 4
28 Hyperbaric Oxygen Therapy (HBOT) for Chronic Diabetic Lower Limb Ulcers Completed NCT00621608 Phase 4
29 Evaluation of Woulgan in Diabetic Foot Ulcer Recruiting NCT02631512 Phase 4
30 A Feasibility Study of the ReGenerCell™ Autologous Cell Harvesting Device for Diabetic Foot Ulcers Recruiting NCT02799121 Phase 4
31 GrafixPL PRIME Evaluation Case Study Recruiting NCT03742440 Phase 4
32 Chlorhexidine Gluconate Solution at 0.125% vs Placebo for the Healing of Grade IIB Ulcers of Diabetic Foot Recruiting NCT03209466 Phase 4 Chlorhexidine gluconate at 0.125%;Placebo Comparator with physiological saline sterile solution
33 A Comparison of TCC-EZ Using Human Amnion Allograft vs TCC-EZ and Standard Wound Care in Treating Diabetic Foot Ulcers. Active, not recruiting NCT02344329 Phase 4
34 TruSkin®: Study for the Treatment of Chronic Diabetic Foot Ulcers Terminated NCT02936115 Phase 4
35 A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers Terminated NCT01858545 Phase 4
36 Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers Terminated NCT02015910 Phase 4 Sitagliptin;Placebo
37 Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers Terminated NCT01108263 Phase 4 INTEGRA™ Flowable Matrix (Collagen)
38 RESPOND Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs Terminated NCT01608776 Phase 4
39 A Randomized, Controlled Trial of Autologous Platelet Gel Treatment in Diabetic Foot Ulcers Withdrawn NCT00338702 Phase 4
40 A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers Withdrawn NCT02248077 Phase 4
41 A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds Withdrawn NCT02120755 Phase 4
42 Use of Santyl Within an Accountable Care Organization Withdrawn NCT02716519 Phase 4
43 a Randomized Controlled Trial Comparing Medical and Medical-surgical Treatment in Diabetic Foot Osteomyelitis Withdrawn NCT00578890 Phase 4
44 Monochromatic Phototherapy on Diabetic Foot Ulcers Unknown status NCT00859599 Phase 3
45 A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers Unknown status NCT01824407 Phase 3
46 Can Topical Oxygen Therapy (Natrox™) Improve Wound Healing in Diabetic Foot Ulcers? Unknown status NCT02599805 Phase 3
47 Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer. Unknown status NCT02554851 Phase 3 recombinant human Epidermal Growth Factor (rhEGF)
48 Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers Unknown status NCT02447172 Phase 3 Gentamicin Collagen sponge
49 Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers Unknown status NCT02427802 Phase 3 Gentamicin collagen sponge
50 Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer Unknown status NCT00521937 Phase 3

Search NIH Clinical Center for Diabetic Foot Ulcers

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diabetic Foot Ulcers cell therapies at LifeMap Discovery.

Genetic Tests for Diabetic Foot Ulcers

Anatomical Context for Diabetic Foot Ulcers

MalaCards organs/tissues related to Diabetic Foot Ulcers:

41
Skin, Bone, Endothelial, Bone Marrow, Colon, Heart, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Diabetic Foot Ulcers:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Diabetic Foot Ulcers

Articles related to Diabetic Foot Ulcers:

(show top 50) (show all 1420)
# Title Authors Year
1
Dysfunctional Wound Healing in Diabetic Foot Ulcers: New Crossroads. ( 29362914 )
2018
2
Polymicrobial interactions influence the agr copy number in Staphylococcus aureus isolates from diabetic foot ulcers. ( 29796774 )
2018
3
Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers. ( 29963295 )
2018
4
Use of Oxidized Regenerated Cellulose/Collagen Matrix in Chronic Diabetic Foot Ulcers: A Systematic Review. ( 29346146 )
2018
5
Growth factors for diabetic foot ulcers: mixed treatment comparison analysis of randomized clinical trials. ( 29148070 )
2018
6
Chinese medicine ulcer oil promotes the healing of diabetic foot ulcers. ( 29916286 )
2018
7
Topical 5% potassium permanganate solution accelerates the healing process in chronic diabetic foot ulcers. ( 29435274 )
2018
8
Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial. ( 29902542 )
2018
9
Perception of diabetic foot ulcers among general practitioners in four European countries: knowledge, skills and urgency. ( 29738299 )
2018
10
Financial burden of diabetic foot ulcers to world: a progressive topic to discuss always. ( 29344337 )
2018
11
Short-term predictors of amputation in patients with diabetic foot ulcers. ( 29802073 )
2018
12
Association between QTc interval prolongation and outcomes of diabetic foot ulcers: Data from a 4-year follow-up study in China. ( 29382590 )
2018
13
Ultrasound-assisted debridement of neuroischaemic diabetic foot ulcers, clinical and microbiological effects: a case series. ( 29738301 )
2018
14
Update on management of diabetic foot ulcers. ( 29377202 )
2018
15
Severe Vitamin D3 Deficiency in the Majority of Patients with Diabetic Foot Ulcers. ( 29975973 )
2018
16
Infected Diabetic Foot Ulcers: No Laterality? ( 29890553 )
2018
17
Osteopontin levels in plasma, muscles, and bone in patient with non-healing diabetic foot ulcers: A new player in wound healing process? ( 29871782 )
2018
18
Nanosphere-mediated co-delivery of VEGF-A and PDGF-B genes for accelerating diabetic foot ulcers healing in rats. ( 29955127 )
2018
19
Effect of negative pressure wound therapy on molecular markers in diabetic foot ulcers. ( 29758297 )
2018
20
Increasing SBP variability is associated with an increased risk of developing incident diabetic foot ulcers. ( 29794815 )
2018
21
CODIFI (Concordance in Diabetic Foot Ulcer Infection): a cross-sectional study of wound swab versus tissue sampling in infected diabetic foot ulcers in England. ( 29391370 )
2018
22
Role of anaerobes in polymicrobial communities and biofilms complicating diabetic foot ulcers. ( 29863794 )
2018
23
Growth factors in the pathogenesis of diabetic foot ulcers. ( 28930549 )
2018
24
Electromagnetic simulation of non-invasive approach for the diagnosis of diabetic foot ulcers. ( 29881185 )
2018
25
Characterization of the Cicatrization Process in Diabetic Foot Ulcers Based on the Production of Reactive Oxygen Species. ( 29951552 )
2018
26
Intervention planning for the REDUCE maintenance intervention: a digital intervention to reduce reulceration risk among patients with a history of diabetic foot ulcers. ( 29779008 )
2018
27
Specific PKC I^ II Inhibitor: One Stone Two Birds in the Treatment of Diabetic Foot Ulcers. ( 29440456 )
2018
28
Characteristics, prevalence, and outcomes of diabetic foot ulcers in Africa. A systemic review and meta-analysis. ( 29807105 )
2018
29
Presence of chronic diabetic foot ulcers is associated with more frequent and more advanced retinopathy. ( 29791040 )
2018
30
Recurrence of Critical Limb Ischemia After Endovascular Intervention in Patients with Diabetic Foot Ulcers. ( 29892493 )
2018
31
Platelet rich plasma and growth factors cocktails for diabetic foot ulcers treatment: State of art developments and future prospects. ( 29050916 )
2018
32
Minimally Invasive Distal Metatarsal Diaphyseal Osteotomy (DMDO) for Chronic Plantar Diabetic Foot Ulcers. ( 29110516 )
2018
33
Bacteriophage Treatment of Infected Diabetic Foot Ulcers. ( 29119439 )
2018
34
Ciprofloxacin-loaded calcium alginate wafers prepared by freeze-drying technique for potential healing of chronic diabetic foot ulcers. ( 29134555 )
2018
35
Evaluation of genotyping methods and costs for IL1α polymorphisms in Platelet Rich-Plasma (PRP); viewpoint for therapy on the diabetic foot ulcers. ( 29461582 )
2018
36
Diabetic Foot Ulcers Heal With Shock Wave Therapy. ( 29466575 )
2018
37
Surgical offloading procedures for diabetic foot ulcers compared to best non-surgical treatment: a study protocol for a randomized controlled trial. ( 29467829 )
2018
38
An exploratory study on differences in cumulative plantar tissue stress between healing and non-healing plantar neuropathic diabetic foot ulcers. ( 29477099 )
2018
39
Potential cost-effectiveness of using a collagen-containing dressing in managing diabetic foot ulcers in the UK. ( 29509110 )
2018
40
Delayed referral of patients with diabetic foot ulcers across Europe: patterns between primary care and specialised units. ( 29509115 )
2018
41
Current Challenges and Opportunities in the Prevention and Management of Diabetic Foot Ulcers. ( 29559450 )
2018
42
The Proteolytic Fraction from Latex of Vasconcellea cundinamarcensis (P1G10) Enhances Wound Healing of Diabetic Foot Ulcers: A Double-Blind Randomized Pilot Study. ( 29564750 )
2018
43
Relationship between plasma angiogenic growth factors and diabetic foot ulcers. ( 29614308 )
2018
44
The Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification independently predicts wound healing in diabetic foot ulcers. ( 29622357 )
2018
45
An evaluation of an ultrasonic debridement system in patients with diabetic foot ulcers: a case series. ( 29637829 )
2018
46
Association of Hemoglobin A1c and Wound Healing in Diabetic Foot Ulcers. ( 29661917 )
2018
47
An aseptically processed, acellular, reticular, allogenic human dermis improves healing in diabetic foot ulcers: A prospective, randomised, controlled, multicentre follow-up trial. ( 29682897 )
2018
48
Efficacy and safety of the combination of isosorbide dinitrate spray and chitosan gel for the treatment of diabetic foot ulcers: A double-blind, randomized, clinical trial. ( 29682995 )
2018
49
Effectiveness of viable cryopreserved placental membranes for management of diabetic foot ulcers in a real world setting. ( 29683538 )
2018
50
Factors associated with amputation among patients with diabetic foot ulcers in a Saudi population. ( 29703224 )
2018

Variations for Diabetic Foot Ulcers

Expression for Diabetic Foot Ulcers

Search GEO for disease gene expression data for Diabetic Foot Ulcers.

Pathways for Diabetic Foot Ulcers

Pathways related to Diabetic Foot Ulcers according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.14 CCL2 IL6 PDGFB TGFB1
2
Show member pathways
13.04 CCL2 IL6 MMP9 PDGFB TGFB1
3
Show member pathways
13.03 CCL2 IL6 PDGFB TGFB1
4
Show member pathways
12.78 CCL2 IL6 PDGFB TGFB1
5
Show member pathways
12.69 CCL2 IL6 MMP9 PDGFB TGFB1
6 12.57 IL6 MMP9 PDGFB TGFB1
7
Show member pathways
12.53 IL6 MMP9 PDGFB
8
Show member pathways
12.51 MMP9 PDGFB TGFB1
9
Show member pathways
12.47 IL6 PDGFB TGFB1
10
Show member pathways
12.35 CCL2 IL6 PDGFB
11 12.21 IL6 PDGFB TGFB1
12
Show member pathways
12.16 IL6 PDGFB TGFB1
13
Show member pathways
12.11 CCL2 IL6 MMP9
14
Show member pathways
12.03 IL6 PDGFB TGFB1
15 11.98 IL6 MMP9 TGFB1
16 11.89 CCL2 MMP9 PDGFB
17 11.86 IL6 PDGFB TGFB1
18
Show member pathways
11.77 CCL2 IL6 PDGFB TGFB1
19 11.74 CCL2 IL6 MMP9
20 11.68 CCL2 IL6 TGFB1
21 11.64 CCL2 IL6 MMP9 TGFB1
22 11.63 CCL2 IL6 TGFB1
23 11.6 CCL2 MMP9 TGFB1
24 11.56 IL6 TGFB1
25
Show member pathways
11.51 PDGFB TGFB1
26 11.51 CCL2 IL6 MMP9 TGFB1
27 11.5 IL6 PDGFB TGFB1
28 11.49 MMP9 TGFB1
29 11.49 IL6 MMP9
30
Show member pathways
11.47 IL6 MMP9
31 11.37 IL6 TGFB1
32 11.35 CCL2 IL6
33 11.34 IL6 MMP9
34 11.3 CALCA IL6
35 11.3 CCL2 IL6 TGFB1
36 11.23 IL6 PDGFB TGFB1
37 11.14 CCL2 MMP9
38 11.11 CCL2 IL6 MMP9 TGFB1
39 11.09 IL6 TGFB1
40 11.03 CCL2 IL6 MMP9
41 11.02 CCL2 MMP9
42 10.99 MMP9 PDGFB
43 10.9 CALCA CCL2 IL6 MMP9 PDGFB TGFB1
44 10.82 MMP9 TGFB1
45 10.77 CCL2 IL6 PDGFB TGFB1

GO Terms for Diabetic Foot Ulcers

Cellular components related to Diabetic Foot Ulcers according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.43 CALCA CCL2 IL6 MMP9 PDGFB TGFB1
2 collagen-containing extracellular matrix GO:0062023 9.33 MMP9 PDGFB TGFB1
3 platelet alpha granule lumen GO:0031093 9.26 PDGFB TGFB1
4 extracellular space GO:0005615 9.1 CALCA CCL2 IL6 MMP9 PDGFB TGFB1

Biological processes related to Diabetic Foot Ulcers according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.81 IL6 PDGFB TGFB1
2 positive regulation of apoptotic process GO:0043065 9.76 IL6 MMP9 TGFB1
3 protein phosphorylation GO:0006468 9.76 CALCA CCL2 PDGFB TGFB1
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.7 CCL2 PDGFB TGFB1
5 positive regulation of cell migration GO:0030335 9.69 MMP9 PDGFB TGFB1
6 MAPK cascade GO:0000165 9.67 CCL2 PDGFB TGFB1
7 response to wounding GO:0009611 9.65 PDGFB TGFB1
8 cellular response to organic cyclic compound GO:0071407 9.65 CCL2 TGFB1
9 positive regulation of MAP kinase activity GO:0043406 9.64 PDGFB TGFB1
10 cellular response to growth factor stimulus GO:0071363 9.63 PDGFB TGFB1
11 humoral immune response GO:0006959 9.63 CCL2 IL6
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.62 IL6 PDGFB
13 positive regulation of fibroblast proliferation GO:0048146 9.62 PDGFB TGFB1
14 negative regulation of fat cell differentiation GO:0045599 9.61 IL6 TGFB1
15 positive regulation of blood vessel endothelial cell migration GO:0043536 9.61 PDGFB TGFB1
16 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.6 MMP9 PDGFB
17 positive regulation of cell division GO:0051781 9.59 PDGFB TGFB1
18 embryo implantation GO:0007566 9.58 CALCA MMP9
19 protein kinase B signaling GO:0043491 9.57 CCL2 TGFB1
20 lipopolysaccharide-mediated signaling pathway GO:0031663 9.56 CCL2 TGFB1
21 inflammatory response GO:0006954 9.56 CALCA CCL2 IL6 TGFB1
22 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.55 PDGFB TGFB1
23 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.54 PDGFB TGFB1
24 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.5 IL6 PDGFB TGFB1
25 negative regulation of ossification GO:0030279 9.48 CALCA TGFB1
26 cytokine-mediated signaling pathway GO:0019221 9.46 CCL2 IL6 MMP9 TGFB1
27 positive regulation of calcium ion import GO:0090280 9.43 CCL2 PDGFB
28 positive regulation of chemotaxis GO:0050921 9.4 PDGFB TGFB1
29 negative regulation of bone resorption GO:0045779 9.37 CALCA IL6
30 regulation of signaling receptor activity GO:0010469 9.35 CALCA CCL2 IL6 PDGFB TGFB1
31 monocyte chemotaxis GO:0002548 8.92 CALCA CCL2 IL6 PDGFB

Molecular functions related to Diabetic Foot Ulcers according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.46 CALCA MMP9 PDGFB TGFB1
2 collagen binding GO:0005518 9.26 MMP9 PDGFB
3 cytokine activity GO:0005125 9.13 CCL2 IL6 TGFB1
4 growth factor activity GO:0008083 8.8 IL6 PDGFB TGFB1

Sources for Diabetic Foot Ulcers

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....